

ASCO 2016: Results on Immunoscore® in colon cancer

Dr. Jérôme Galon to present results of the Immunoscore® worldwide SITC¹ study during the Gastrointestinal Cancer Oral Session

Marseille, France, May 23, 2016 – HalioDx SAS, a diagnostic company in immuno-oncology, today announced that key results on Immunoscore® in colon cancer will be presented at the ASCO 2016 annual meeting by Dr Jérôme Galon, Research Director at Inserm, Head of the laboratory of Integrative Cancer Immunology, Paris, France and principal investigator of the study. The presentation entitled “Validation of the Immunoscore® as a prognostic marker in stage I/II/III colon cancer” will focus on the results of a study conducted on thousands of patients by the Immunoscore® worldwide consortium, led by the Society for Immunotherapy of Cancer (SITC).

“Colon cancers, especially stages II and III, are still a challenge that neither conventional prognostic factors nor available biomarkers or expression signatures have managed to overcome. The changing paradigm of evaluating the immune contexture of the tumor instead of focusing solely on tumor cells is a powerful approach, the Immunoscore® Colon assay being the first tangible application of this revolution with the hope for better clinically actionable information for the benefit of patients.” comments Vincent Fert, co-founder and CEO of HalioDx. He adds: *“The Immunoscore® worldwide consortium is the largest study ever undertaken to validate a biomarker. The overall performance of Immunoscore® as recorded in initial studies² suggests that the assay could be a key adjunct to the AJCC/UICC-TNM classification. HalioDx is very excited by the results to be presented by Dr Jérôme Galon at ASCO 2016 as they involved a significant number of patients worldwide and numerous laboratories sites.”*

Oral Abstract Session: Gastrointestinal (Colorectal) Cancer, Sunday Jun 05, 2016 8:00 AM - 11:00 AM

Abstract 3500 - 8:00 AM - 8:12 AM

Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: Results of a worldwide consortium-based analysis of 1,336 patients. Presenter: Jerome Galon, PhD – Inserm

See abstract: http://abstract.asco.org/176/AbstView_176_168666.html

¹ Society for Immunotherapy of Cancer

² Galon J et al. Science 2006, Pagès F et al. JCO 2009, Mlecnik B et al. JCO 2011

About HalioDx SAS

The Immune Response to Cancer Diagnostics

By precisely measuring the immune reaction in and around the tumor, HalioDx tests allow the clinician to determine the degree of severity of the patient's disease and predict the response to treatment, regardless of the cancer stage or the molecular class.

HalioDx designs and develops a unique range of immune scoring tests, whose first-in-class product is Immunoscore®. Considered a future diagnostic standard in Oncology, this biomarker has already demonstrated strong prognostic value in colorectal cancer. HalioDx was founded in 2014 by the former management team of Ipsogen (leader in the molecular diagnosis of leukemia), and a pioneer in integrative immunology and oncology, Dr. Jérôme Galon. HalioDx benefits of worldwide licences on a broad portfolio of IP rights on immuno-oncology biomarkers (including the Immunoscore® technology) developed by Dr. Jérôme Galon, Research Director at Inserm, and his team (Inserm UMRS1138) at Cordeliers Research Center, Paris, France.

HalioDx has an experienced team of 80 employees and compliant facilities to develop, manufacture, deliver and market in vitro diagnostic products and services in immuno-oncology.

For more information, please visit: www.haliodx.com

HalioDx and Immunoscore are registered trademarks.

Contacts

HalioDx

ATCG Press

Marie Puvieux (France), Mob: +33 (0)6 10 54 36 72

Jean-Mehdi Grangeon (ROW), Mob: +33 (0)6 62 22 00 24

haliodx@atcg-partners.com

[Twitter: twitter.com/haliodx](https://twitter.com/haliodx)